Arbutus Biopharma Corporation

ABUS

CA03879J1003

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 02:13:34 2024-05-15 pm EDT			5-day change	1st Jan Change
2.855 ^USD	-0.17%		+0.71%	+14.40%

May. 09	Whitefort Capital Management Engages with Arbutus Biopharma	CI
May. 02	Transcript : Arbutus Biopharma Corporation, Q1 2024 Earnings Call, May 02, 2024

Arbutus Biopharma Corporation Announces Resignation of Gaston Picchio as Chief Development Officer

September 30, 2022 at 09:00 am EDT

Arbutus Biopharma Corporation announced that Gaston Picchio, PhD, Chief Development Officer, will be leaving the Company for personal reasons. Dr. Picchio will continue to serve as CDO until his departure on December 31, 2022. The Company has initiated a search for Dr. Picchio's replacement.

Latest news about Arbutus Biopharma Corporation

Whitefort Capital Management Engages with Arbutus Biopharma	May. 09	CI
Transcript : Arbutus Biopharma Corporation, Q1 2024 Earnings Call, May 02, 2024	May. 02
Earnings Flash (ABUS) ARBUTUS BIOPHARMA CORPORATION Posts Q1 Revenue $1.5M	May. 02	MT
Earnings Flash (ABUS) ARBUTUS BIOPHARMA CORPORATION Posts Q1 Revenue $1.5M, vs. Street Est of $3.7M	May. 02	MT
Arbutus Biopharma Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Arbutus Biopharma Corporation Announces Retirement of Chief Scientific Officer, Michael J. Sofia Effective December 31, 2024	May. 02	CI
Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit	Apr. 05	MT
Moderna Suffers Setback in Lawsuit by Arbutus	Apr. 04	MT
Moderna shares fall after judge sides with Arbutus in patent fight	Apr. 03	RE
Transcript : Arbutus Biopharma Corporation Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 02:05 PM	Mar. 12
HC Wainwright Trims Price Target on Arbutus Biopharma to $5 From $6, Keeps Buy Rating	Mar. 01	MT
Transcript : Arbutus Biopharma Corporation, Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
Arbutus Biopharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Arbutus Biopharma, Inc. Announces Clinical Development Milestones to Advance Its HBV Pipeline	Jan. 08	CI
Arbutus Biopharma Corporation and Barinthus Biotherapeutics plc Present Preliminary Data from Phase 2A Clinical Trial Combining Imdusiran with VTP-300 at AASLD	Nov. 09	CI
Arbutus Biopharma Posts Q3 Net Loss, Lower Revenue; CEO to Retire, 24% Research Staff Cut	Nov. 07	MT
Transcript : Arbutus Biopharma Corporation, Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07
Earnings Flash (ABUS) ARBUTUS BIOPHARMA CORPORATION Posts Q3 Revenue $4.7M, vs. Street Est of $4.7M	Nov. 07	MT
Arbutus Biopharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Arbutus Biopharma Corporation Announces CEO Changes	Nov. 07	CI
Arbutus Biopharma Corporation Announces President Changes	Nov. 07	CI
JMP Securities Adjusts Arbutus Biopharma Price Target to $4 From $6, Maintains Market Outperform Rating	23-09-12	MT
Arbutus Biopharma Discontinues Coronavirus, Oral RNA Destabilizer Programs, Focuses on Hepatitis B Virus Treatment Assets	23-09-11	MT
Arbutus Biopharma Corporation Announces Pipeline Updates and Dosing of First Subject in Phase 1a/1b Clinical Trial with AB-101	23-09-11	CI
Transcript : Arbutus Biopharma Corporation, Q2 2023 Earnings Call, Aug 03, 2023	23-08-03

Chart Arbutus Biopharma Corporation

Duration

Period

More charts

Company Profile

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patientsâ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.

Sector

Pharmaceuticals

Calendar

2024-05-20 - H.C. Wainwright BioConnect Investor Conference - Fireside Chat

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Arbutus Biopharma Corporation

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.904 CAD

Average target price

6.029 CAD

Spread / Average Target

+54.45%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
ARBUTUS BIOPHARMA CORPORATION	+14.40%	540M
CSL LIMITED	-1.26%	89.46B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.74B
BIOGEN INC.	-8.81%	33.03B
UCB	+55.32%	24.68B
BIOMARIN PHARMACEUTICAL INC.	-16.32%	15.12B
INCYTE CORPORATION	-8.88%	12.81B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.11%	11.79B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.61%	11.64B
SWEDISH ORPHAN BIOVITRUM AB	+7.79%	8.9B

Biopharmaceuticals